Skip to main content
SpringerLink
Log in

Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders

  • Original Article
  • Published:
Irish Journal of Medical Science Aims and scope Submit manuscript

Abstract

Background

The chronic myeloproliferative disorders (MPD) are clonal haemopoietic stem cell disorders.

Aims

The incidence of JAK2 V617F mutation was sought in a population of patients with MPD.

Methods

The JAK2 V617 mutation status was determined in 79 patients with known MPD and 59 patients with features suggestive of MPD.

Results

The mutation was found in patients with polycythaemia vera, essential thrombocythaemia, idiopathic myelofibrosis and in patients with other chronic myeloproliferative disorders. Eight JAK2 V617F positive cases were identified amongst those patients with features suggestive of MPD.

Conclusions

The incidence of the JAK2 V617F mutation in MPD patients is similar to that reported by other groups. The assay confirmed and refined the diagnosis of several patients with features indicative of MPD. We suggest screening for this mutation in all patients with known and suspected MPD as identification is valuable in classification and is a potential target for signal transduction therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World health organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon

  2. Hughes T, Branford S (2006) Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 20:29–41

    Article  PubMed  CAS  Google Scholar 

  3. Deininger M, Buchdunger E, Druker BJ (2005) The development of Imatinib as a therapeutic agent for chronic myeloid leukaemia. Blood 105:2640–2653

    Article  PubMed  CAS  Google Scholar 

  4. Frohling S, Scholl C, Gilliland DG, Levine RL (2005) Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 23:6285–6295

    Article  PubMed  CAS  Google Scholar 

  5. Kralovics R, Skoda RC (2005) Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev 19:1–13

    Article  PubMed  CAS  Google Scholar 

  6. Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061

    PubMed  CAS  Google Scholar 

  7. Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Eng J Med 352:1779–1790

    Article  CAS  Google Scholar 

  8. Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397

    Article  PubMed  CAS  Google Scholar 

  9. James C, Ugo V, Le Couedic JP, et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148

    Article  PubMed  CAS  Google Scholar 

  10. Jones AV, Kreil S, Zoi K et al (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162–2168

    Article  PubMed  CAS  Google Scholar 

  11. Zhao R, Xing S, Li Z, Li Q, Krantz SB, Zhao ZJ (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788–22792

    Article  PubMed  CAS  Google Scholar 

  12. Yamaoka K, Saharinen P, Pesu M, Holt VET, Silvennoinen O, O’Shea JJ (2004) The janus kinases (Jaks). Genome Biol 5:253

    Article  PubMed  Google Scholar 

  13. Kaushansky K (2005) On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 105:4187–4190

    Article  PubMed  CAS  Google Scholar 

  14. Jelinek J, Oki Y, Gharibyan V et al (2005) JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML and megakaryoblastic leukaemia. Blood 106:3370–3373

    Article  PubMed  CAS  Google Scholar 

  15. Levine RL, Loriaux M, Huntly BJ et al (2005) The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukaemia and acute myeloid leukaemia, but not in acute lymphoblastic leukaemia or chronic lymphocytic leukaemia. Blood 106:3377–3379

    Article  PubMed  CAS  Google Scholar 

  16. Lee JW, Kim YG, Soung YH et al (2006) The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 25:1434–1436

    Article  PubMed  CAS  Google Scholar 

  17. Ohyashiki K, Aota Y, Akahane D et al (2005) The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 19:2359–2360

    Article  PubMed  CAS  Google Scholar 

  18. Tono C, Xu G, Toki T et al (2005) JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukaemia. Leukemia 19:1843–1844

    Article  PubMed  CAS  Google Scholar 

  19. McLornan DP, Percy MJ, Jones AV, Cross NC, McMullin MF (2005) Chronic neutrophilic leukaemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica 90:1696–1697

    CAS  Google Scholar 

  20. Melzner I, Weniger MA, Menz CK, Moller P (2006) Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia 20:157–158

    Article  PubMed  CAS  Google Scholar 

  21. Lee JW, Soung YH, Kim SY et al (2006) JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas. Leuk Lymphoma 47:313–314

    Article  PubMed  CAS  Google Scholar 

  22. Sulong S, Case M, Minto L, Wilkins B, Hall A, Irving J (2005) The V617F mutation in JAK2 is not found in childhood acute lymphoblastic leukaemia. Brit J Haematol 130:964–965

    Article  Google Scholar 

  23. van Dongen JJ, Macintyre EA, Gabert JA et al (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukaemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukaemia. Leukemia 13:1901–1928

    Article  PubMed  Google Scholar 

  24. Campbell PJ, Green AR (2005) Management of polycythemia vera and essential thrombocythemia. Hematology (Am Soc Hematol Educ Program), pp 201–208

  25. Johan MF, Goodeve AC, Bowen DT, Frew MF, Reilly JT (2005) JAK2 V617F mutation is uncommon in chronic myelomonocytic leukaemia. Brit J Haematol 130:968

    Article  CAS  Google Scholar 

  26. Steensma DP, Dewald GW, Lasho TL et al (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes. Blood 106:1207–1209

    Article  PubMed  CAS  Google Scholar 

  27. Scott LM, Campbell PJ, Baxter EJ et al (2005) The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 106:2920–2921

    Article  PubMed  CAS  Google Scholar 

  28. Tefferi A, Lasho TL, Schwager SM et al (2006) The clinical phenotype of wild-type, heterozygous and homozygous JAK2 (V617F) in polycythemia vera. Cancer 106:631–635

    Article  PubMed  CAS  Google Scholar 

  29. Wolanskyj AP, Lasho TL, Schwager SM et al (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Brit J Haematol 131:208–213

    Article  CAS  Google Scholar 

  30. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C (2006) The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Brit J Haematol 132:244–245

    Article  CAS  Google Scholar 

  31. Tefferi A, Lasho TL, Schwager SM et al (2005) The JAK2 (V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Brit J Haematol 131:320–328

    Article  CAS  Google Scholar 

  32. Campbell PJ, Griesshammer M, Dohner K et al (2006) The V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107:2098–2100

    Article  PubMed  CAS  Google Scholar 

  33. Bench A, Li J, Huntly BJ et al (2004) Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies. Brit J Haematol 127:509–518

    Article  CAS  Google Scholar 

  34. Futterer A, Campanero MR, Leonardo E et al (2005) Dido gene expression alterations are implicated in the induction of haematological myeloid neoplasms. J Clin Invest 115:2351–2362

    Article  PubMed  CAS  Google Scholar 

  35. Chalandon Y, Schwaller J (2005) Targeting mutated protein tyrosine kinases and their signalling pathways in hematologic malignancies. Haematologica 90:949–968

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors are grateful to Professor S. McCann, Dr P. Browne and Dr E. Vandenberghe, Department of Haematology, St. James’s Hospital, Dublin and all other clinicians who have provided patient material for molecular investigation of MPD.

Author information

Authors and Affiliations

  1. Cancer Molecular Diagnostics, Central Pathology Laboratory, St. James’s Hospital, Dublin 8, Ireland

    S. E. Langabeer & M. Lawler

  2. Department of Haematology, St. James’s Hospital, Dublin, Ireland

    F. Ni Ainle & E. Conneally

  3. Institute of Molecular Medicine, St. James’s Hospital and Trinity College Dublin, Dublin, Ireland

    M. Lawler

Authors
  1. S. E. Langabeer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Ni Ainle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Conneally
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Lawler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. E. Langabeer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Langabeer, S.E., Ni Ainle, F., Conneally, E. et al. Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. Ir J Med Sci 176, 105–109 (2007). https://doi.org/10.1007/s11845-007-0026-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-007-0026-x

Keywords

Search

Navigation